We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

Fund managers haven’t disclosed any holdings of ENTA yet.

ENTA Hedge Fund Activity: Q1 2026 in Review

132 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2026, worth a combined $338M — down 19% from $416M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ENTA positions and 21 closed out — a net gain of 3 holders — while 49 added to existing stakes and 33 trimmed.

The largest buyer was Spruce Street Capital, adding an estimated $7.28M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.92M sold.

  • 132 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2026, up from 131 in Q4 2025.
  • Funds reported $338M of Enanta Pharmaceuticals stock for Q1 2026, down 19% quarter-over-quarter.
  • 24 funds opened new Enanta Pharmaceuticals positions in Q1 2026 and 21 closed out, a net change of +3 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2026 was Spruce Street Capital, an estimated $7.28M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $6.92M sold.

Based on aggregated 13F filings for Q1 2026.